Amor VAM, Díaz ACA, Fernández ML

Language: Spanish
References: 13
Page: 1-7
PDF size: 662.49 Kb.

ABSTRACT

Chronic myeloid leukemia is characterized by the occurrence of a reciprocal translocation between chromosomes 9 and 22; which gives rise to a derivative chromosome 22 known as Philadelphia. At the binding site, the BCR-ABL fusion gene is formed, which leads to the synthesis of a hybrid protein with oncogenic properties. The binding site between chromosomes 9 and 22 is variable and gives rise to different transcripts; those known as e13a2 and e14a2 are the most frequent and studied. The analysis of the clinical-hematological characteristics of presentation and the response to treatment among patients with e13a2 or e14a2 has revealed differences that may be useful for the prediction of prognosis. To describe the different characteristics reported for one or another transcript and to know if it is important to know the type of transcript in the CML. A review of the scientific literature was carried out through PUBMED. The information was analyzed and summarized. Different presentation characteristics are evident but there is no coincidence between all the authors. Regarding the behavior of the response to treatment with tyrosine kinase inhibitors, some authors find differences and some suggest that it may be two different entities. It may be important to know the type of BCR-ABL transcript in CML cause, at least between the two most frequent, there are differences that may be useful in predicting the prognosis for the patient as well as for the management of treatment.

REFERENCES

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapyand monitoring. Am J Hematol. 2020;95(6):691-709. DOI: https://10.1002/ajh.257921.

2. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, Mc Credie KB, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J. Clin. Oncol. 1986;4(7):1079-88. DOI: https://10.1200/JCO.1986.4.7.10792.

3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375-84.

4. . Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor, Chronic myeloid leukemia. Switzerland: Springer International Publishing;2016.p.17-40

5. Greenfield G, McMullan R, Robson N, McGimpsey J, Catherwood M, McMullin MF. Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol. 2019 May 2;19:7. doi: 10.1186/s12878-019-0139-2.

6. Molica M, Abruzzese E, Breccia M. Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020062. DOI: https://10.4084/MJHID.2020.0626.

7. Amin H, Ahmed S. Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia. Open Med. 2021;16(1):904-12. DOI: https://10.1515/med-2021-03097.

8. Castagnetti F,Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017;92(8):797-805. DOI: https://10.1002/ajh.247748.

9. . D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, et al. The e13a2 BCR-ABL Transcript Negatively Affects Sustained Deep Molecular Response and the Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Receive Tyrosine Kinase Inhibitors. Cancer. 2019; 125(10):1674-82. DOI: https://1002/cncr.31977 9.

10. Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronicmyeloid leukemia. An international overview. Leukemia. 2019;33(5):1173-83. DOI: https://10.1038/s41375-018-0341-410.

11. de Almeida Filho TP, Maia Filho PA, Cavalcante Barbosa M, Alves Dutra LL, de Castro M F, Barroso Duarte F, et al11. . Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? Hematol Transfus Cell Ther. 2019;41(2):114-8. DOI: https://doi.org/10.1016/j.htct.2018.10.00311.

12. Amor-Vigil AM, González-Medina Y, Cayado-Gutiérrez N, Martínez-Antuña G. Frecuencia de los transcriptos BCR-ABL en pacientes cubanos con leucemia mieloide crónica. Rev Cubana Hematol Immunol Hemoter. 2012;28(4):8.

13. Jain P, Kantarjian H, Shamanna RK, Daver N, Patel KP, Sasaki K, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127(10):1269-75. DOI: https://10.1182/blood-2015-10-67424213.